NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD
NASDAQ:BCLI (2/21/2025, 8:02:56 PM)
1.73
-0.07 (-3.89%)
The current stock price of BCLI is 1.73 USD. In the past month the price decreased by -19.91%. In the past year, price decreased by -66.95%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Brainstorm Cell Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 29 full-time employees. The company went IPO on 2003-05-28. BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The firm is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. The company has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
BRAINSTORM CELL THERAPEUTICS
1325 Avenue Of Americas, 28th Floor
New York City NEW YORK 10019 US
CEO: Chaim Lebovits
Employees: 29
Company Website: https://brainstorm-cell.com/
Investor Relations: http://ir.brainstorm-cell.com
Phone: 12014880460
The current stock price of BCLI is 1.73 USD. The price decreased by -3.89% in the last trading session.
The exchange symbol of BRAINSTORM CELL THERAPEUTICS is BCLI and it is listed on the Nasdaq exchange.
BCLI stock is listed on the Nasdaq exchange.
8 analysts have analysed BCLI and the average price target is 14.11 USD. This implies a price increase of 715.8% is expected in the next year compared to the current price of 1.73. Check the BRAINSTORM CELL THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRAINSTORM CELL THERAPEUTICS (BCLI) has a market capitalization of 9.86M USD. This makes BCLI a Nano Cap stock.
BRAINSTORM CELL THERAPEUTICS (BCLI) currently has 29 employees.
BRAINSTORM CELL THERAPEUTICS (BCLI) has a support level at 1.71 and a resistance level at 1.81. Check the full technical report for a detailed analysis of BCLI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BCLI does not pay a dividend.
BRAINSTORM CELL THERAPEUTICS (BCLI) will report earnings on 2025-03-31, after the market close.
BRAINSTORM CELL THERAPEUTICS (BCLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.46).
The outstanding short interest for BRAINSTORM CELL THERAPEUTICS (BCLI) is 2.05% of its float. Check the ownership tab for more information on the BCLI short interest.
ChartMill assigns a technical rating of 1 / 10 to BCLI. When comparing the yearly performance of all stocks, BCLI is a bad performer in the overall market: 80.82% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to BCLI. Both the profitability and financial health of BCLI have multiple concerns.
Over the last trailing twelve months BCLI reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -685.58% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -702.62% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 85% to BCLI. The Buy consensus is the average rating of analysts ratings from 8 analysts.